Evidence map›Paper›PMID 26811651›Full record

ReviewWorld journal of gastroenterology2016

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Ramakrishnan Ayloor Seshadri, Olivier Glehen

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02672865 (Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer), which is not on this map. Cited by 53 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 6 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02672865 phase1completednot on this map

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer

TypeinterventionalSponsorLoma Linda UniversityRan2016 to 2018Enrolled4ConditionsLocally Advanced Malignant Neoplasm, Gastric CancerArmsHyperthermic Intraperitoneal Chemotherapy (HIPEC)
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Ramakrishnan Ayloor SeshadriRamakrishnan Ayloor Seshadri, Department of Surgical Oncology, Cancer Institute (WIA), Chennai 600036, India.
Olivier GlehenRamakrishnan Ayloor Seshadri, Department of Surgical Oncology, Cancer Institute (WIA), Chennai 600036, India.
Hôpital Lyon Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer associated peritoneal carcinomatosis (GCPC) has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in GCPC. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been investigated for GCPC. HIPEC has been used for three indications in GC- as an adjuvant therapy after a curative surgery, HIPEC has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, HIPEC along with CRS is the only therapeutic modality that has resulted in long-term survival in select groups of patients; as a palliative treatment in advanced PC with intractable ascites, HIPEC has been shown to control ascites and reduce the need for frequent paracentesis. While the results of randomised trials of adjuvant HIPEC from western centres are awaited, the role of HIPEC in the treatment of GCPC is still evolving and needs larger studies before it is accepted as a standard of care.

Indexed as

Cytoreduction Surgical ProceduresHyperthermia, InducedAntineoplastic AgentsChemotherapy, AdjuvantHumansPalliative CarePeritoneal NeoplasmsRisk FactorsStomach NeoplasmsTreatment OutcomeAntineoplastic AgentsCytoreductive surgeryGastric cancerHyperthermic intraperitoneal chemotherapyPeritoneal carcinomatosis

Identifiers

PMID26811651
PMCPMC4716024
OpenAlexW2411757157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.